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Abstract: National health care registries in the Nordic countries share many attributes, but 
different legal and ethical frameworks represent a challenge to promoting effective joint research. 
Internationally, there is a lack of knowledge about how ethical matters are considered in Nordic 
registry-based research, and a lack of knowledge about how Nordic ethics committees operate and 
what is needed to obtain an approval. In this paper, we review ethical aspects of registry-based 
research, the legal framework, the role of ethics review boards in the Nordic countries, and the 
structure of the ethics application. We discuss the role of informed consent in registry-based 
research and how to safeguard the integrity of study participants, including vulnerable subjects 
and children. Our review also provides information on the different government agencies that 
contribute registry-based data, and a list of the major health registries in Denmark, Finland, 
Iceland, Norway, and Sweden. Both ethical values and conditions for registry-based research 
are similar in the Nordic countries. While Denmark, Finland, Iceland, Norway, and Sweden have 
chosen different legal frameworks, these differences can be resolved through mutual recognition 
of ethical applications and by harmonizing the different systems, likely leading to increased 
collaboration and enlarged studies.
Keywords: ethical review, ethics, institutional review board, Nordic countries, registry-based 
research, informed consent
Introduction
National population-based registries (Table S1), virtually free health care1 (costs are 
covered through the tax bill), a high degree of public trust in research,2 plus the belief 
in social equality and mutual responsibility and the existence of personal identity 
numbers (PINs) allowing unambiguous linkage of large-scale data3,4 all contribute to 
the success of epidemiological research in the Nordic countries (Denmark, Finland, 
Iceland, Norway, and Sweden). A mandatory prerequisite for continued use of 
national health care data for medical research is, however, that the personal integrity 
of participating individuals is guaranteed.
Population-based registry data have been extensively used to examine a number 
of important areas in which other study designs may be unethical or difficult to use, 
including the association between type 1 diabetes and other autoimmune diseases,5 
the recurrence of preeclampsia,6 the association between birth characteristics and later 
cardiovascular disease,7 substance abuse, and the risk of psychotic disorders in epilepsy,8 
as well as the risk of fetal death following maternal vaccination against influenza.9
While a similar cultural background and a history of collaboration in the Nordic 
countries encourage multilateral research projects, differences in legal and ethical 
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frameworks represent obstacles for collaborative initiatives. 
The aim of the current work was to review ethical aspects 
of registry-based research, the ethics application (EA), and 
the role of ethics committees (ECs) in the Nordic countries. 
Currently, approval from each national EC in the Nordic 
countries is needed to conduct trans-Nordic research.
The EC
Organization and election of members
Before a medical project is initiated, approval from an EC 
is required. ECs (also called “ethics review boards”, “ethics 
vetting boards”, or “institutional review boards” [IRBs]) 
are made up of both professional and lay representatives 
(Table 1). Members of the EC are usually appointed by 
academic or research institutions or by the government. 
Table 1 gives an overview of the ECs in the Nordic countries. 
Greenland follows the Danish legislation, and their ethical 
committee follows the practices of the Danish ethical 
committee system. In Faroe Islands, the legislation is also 
similar to that of Denmark, and The Faroese Committee on 
Biomedical Research Ethics generally follows the practices 
of the Danish ethical committee system.
With the exception of Iceland, ECs in all Nordic countries 
are regional. The geographic responsibility of each EC often 
coincides with that of a specific health care region, but that 
does not necessarily imply that the EC per se is linked to 
a specific hospital. For instance, the largest EC in Sweden 
is “the EC in Stockholm” and not “the EC of Karolinska 
Institutet”.
The central EC
Decisions in a regional EC can be appealed to the central EC. 
Appeals are uncommon for registry-based research in that 
ECs tend to see that the advantages of the research outweigh 
the disadvantages (and therefore approve most EAs).10
The central EC of Sweden considers appeals from 
researchers whose applications to a regional EC have been 
rejected. Furthermore, the central EC of Sweden supervises 
and ensures that relevant laws and regulations (Law 2003:640, 
§34) are strictly followed.11 The central EC in Sweden also 
investigates potential scientific misconduct.
In Finland, there is one central EC, the National Com-
mittee on Medical Research Ethics, which belongs to the 
National Supervisory Authority for Welfare and Health (Val-
vira), which, in turn, operates under The Ministry of Social 
Affairs and Health. The role of the committee is to support 
and coordinate activities of the regional ECs concerning the 
processes of the statements/opinions as well as principled 
research ethical questions. In addition, the committee gives 
national statements/opinions on clinical drug trials, unless the 
statements/opinions have been relinquished to a regional EC. 
The central EC also reviews and gives an opinion to the regional 
EC when a regional EA has been rejected. In these cases, the 
central EC reviews the application in its original version.
The central committee also participates in international 
collaboration on research regarding ethical issues. The 
committee collects and mediates information about issues 
in research and mediates information about international 
ethical discussions through such venues as publications and 
training occasions. Finally, the committee promotes a national 
discussion about medical and biomedical research.12
In Iceland, there is one central EC, the National Bioethics 
Committee, which evaluates collaborative projects, multina-
tional projects, clinical trials of medicinal products, and other 
prospective scientific research projects in the health sector.13 
Additionally, there are the Health Research Ethics Com-
mittees maintained at two major hospitals, the Landspítali 
University Hospital, Reykjavík, Iceland, and the Akureyri 
Hospital, Akureyri, Iceland for research projects in the health 
sector to be carried out at these institutions. All applications 
concerning clinical trials and international cooperation are, 
however, submitted to the central National Bioethics Com-
mittee. The ECs in Iceland forward a list of all applications 
to the Data Protection Authority for review, and in some 
cases, further approval of research pertaining to protection 
of individual privacy and security of data processing.
In Denmark, there is one central EC, The National Commit-
tee on Health Research Ethics (DNVK). In addition to acting 
as board of appeal in connection with decisions made in the 
regional ECs, the DNVK coordinates activities in the regional 
committees, writes guidelines, gives opinions on issues of a fun-
damental nature (if these opinions are not related to the approval 
of a concrete research project), monitors the development of 
research within the health sector, and promotes the under-
standing of ethical problems resulting from this development. 
Finally, the DNVK makes recommendations to the Minister 
of the Interior and Health and provides consultative statements 
on biomedical research projects planned by Danish researchers 
for implementation in developing countries.
In Norway, the National Committee for Medical and 
Health Research Ethics (NEM) coordinates the seven 
regional ECs for medical and health research. The National 
Committee for Research Ethics in the Social Sciences and 
Humanities and the National Committee for Research Ethics 
in Science and Technology are National ECs that draw up 
guidelines and provide advice to individual projects within 
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their fields. The National Commission for the Investigation of 
Research Misconduct may investigate allegations and suspi-
cions of misconduct in research, and the National Committee 
for Research Ethics on Human Remains evaluates the ethical 
aspects of research in which the source material consists of 
human remains from museums, collections, and archeologi-
cal excavations. NEM was set up in 1990 and serves as an 
advisory and place of appeal for the seven regional ECs. NEM 
offers its opinion on issues that are a matter of principle, 
prepares guidelines and reports, and organizes open discus-
sion forums on various ethical topics related to research. The 
national committees meet biannually to coordinate relevant 
issues. All members of NEM and the regional ECs attend an 
annual joint meeting for professional discussion.
Time-limited validity of EAs
As opposed to approvals from, for instance, the American 
IRBs,14 the validity of the approvals of Swedish ECs is not 
time-limited (and hence no annual approval is needed), but 
an approved project must start within 2 years from the date of 
approval.15 For projects with funding from the US National 
Institutes of Health (NIH), Swedish ECs may sometimes 
certify that annual ethics approvals are not needed according 
to Swedish law.
In Finland, a re-approval is needed when there is a change, 
addition, or update concerning the project and research 
plan, from an ethical point of view.16 Finnish researchers 
must also state a starting and ending date in the application 
form. In Iceland, the approval is time-limited, depending on 
each project and application.17 After that, a re-approval, or 
an amendment in case of deviations from the original study 
protocol, is required to carry on the research. In Denmark, 
the approval from the EC covers the project as it is described 
in the application, and no annual re-approvals are necessary.18 
In case of deviations from the approved protocol (eg, inclu-
sion of new biomarkers or prolongation of the study period), 
an amendment to the original protocol must be approved. 
For registry-based research, only projects that incorporate 
biological material require an EC approval, so most Danish 
registry-based studies are covered by an approval from the 
Danish Data Protection Agency. These latter approvals cover 
a specified period (eg, 5 or 10 years) and must be re-approved 
after the fixed period.
In Norway, the ECs approve the projects with a set start and 
end date of the project (typically 5 years). The projects do not 
report annually to the ECs, but must apply for a re-approval 
whenever a change occurs in the project (eg, new project mem-
bers, changes in aims or data collection, or prolongation of the 
study period). Since July 1, 2009, Norwegian researchers must 
also submit a report to the EC at the end of the project (ACT 
2008-06-20 number 44, chapter 4, § 12). For projects includ-
ing data from the prescription database, an approval from the 
Norwegian Data Protection Agency is mandatory.
The EA
In this section, we describe an EA, but with special focus on those 
parts that are of particular relevance to registry-based research. 
Project-specific information (such as title, scientific background, 
hypothesis, and methods) is not treated in this paper.
The applicant
In all Nordic countries except Sweden, the principal investi-
gator (PI) is the main applicant of the EA (the only exception 
being student projects in which case, the student supervisor is 
the applicant) (Table 2). Usually, the PI is also the guarantor 
of the study.16 In Sweden, the PIs are the contact persons, but 
Table 2 Content of ethics application (EA)
Country Someone other  
than the principal  
investigator (PI)  
needs to sign the EA
Data key∞ Must be discussed and reported in the EA
How to store  
personal data
Power calculation# Informed consent Relationship between 
the researcher and  
the research subject
Denmark## No Yes‡ No Yes Yes No
Finland No Yes Yes Yes Yes Yes
iceland No Yes Yes No Yes Yes
Norway Yes* Yes** Yes Yes Yes Yes
Sweden Yes, head of department*** Yes Yes Yes Yes Yes
Notes: *in Norway, according to the Health Research Act, medical and health research must be organized as a project under the direction of a person or body responsible 
for the research. Typically, this will be at an institutional level, and as such, the head of the department, division, or section needs to approve the application; **some data 
owners and registries, such as the Norwegian Prescription Registry, do not allow that a key is preserved between a person’s personal identity number (PiN) and the 
research identifier; ***to eliminate projects without basic resources, the head of the department must sign the EA to guarantee that the responsible researcher has access 
to 1) resources adequate to finish the project and 2) a physical workplace from where the project can be conducted; #the EC requests a power calculation. This calculation 
ensures that the study does not waste resources (ie, is unethical) and do not waste study participants’ time without being able to answer the main research question; ##in 
the case of multi-center trials, the investigator should only apply for permission from the regional committee in the area, where the Pi carries out the research project; ∞key 
between PiNs and data can be preserved; ‡in Denmark, the researchers usually have PiNs included in the delivered dataset.
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their responsible body (usually the university where they are 
affiliated) is the applicant.
The first part of the EA deals with the involved research-
ers and the research body they represent. The research body 
is often the researcher’s employer. Typical research bodies 
include universities, certain government agencies, private 
research institutes, certain foundations, and county councils. 
While the EA must contain a short scientific background, this 
part should typically focus on expected knowledge gains and 
the (clinical) importance of the proposed research. In Sweden, 
Finland, Denmark, and Norway, the ECs require researchers 
to attach separate information for laypersons about the project 
at submission. Swedish ECs stipulate that all information be 
given in Swedish, but in reality, the appended research plan 
may be written in English.
Researchers are expected to outline the data collection 
process in detail and how they plan to monitor data quality. 
Most registry-based research will not 1) deviate from clini-
cal routine; or even 2) involve direct contact with the study 
participants. Hence, no personal consent is needed from the 
study participants to obtain approval from the ECs.
As part of the description of the data collection, the 
sources of data (eg, the Cause of Death Registry) and data 
storage should also be described. Typically, the researcher 
must guarantee that collected data are stored without non-
researchers having access to confidential data. In exceptional 
cases, the government agencies responsible for collection and 
storage of national health care data (Table 3) will supply a 
researcher with identifiable data (more common in Denmark 
than elsewhere [Table 2]), but most often data are distributed 
pseudonymized. True anonymization implies that there is 
no key between the identity of an individual (his/her PIN) 
and the data used by the researcher (where individual study 
participants are usually differentiated by serial numbers). 
Anonymization precludes any additional linkage or clarifica-
tion of improbable data and is, therefore, not ideal in registry-
based research. Pseudonymization means that there is a key 
and an opportunity to define the true identity of individuals 
in a dataset, and eg, to link these individuals to new data if 
needed or to update their medical history.
In addition, in Finland, researchers will receive data 
with full identification in those cases when the participants 
have consented to the study and have released their PIN 
 themselves. However, there are some exceptions, depend-
ing on the registry. For example, data from social welfare 
registries never include PINs; instead, data is pseudony-
mized. The same applies to registry-based research without 
consent.
With pseudonymized data, researchers may request that 
a key file (between the PIN and the serial number) be stored 
at the government agency responsible for the data matching 
(applicable in Sweden, Finland, Norway, and Iceland). There 
is international variation; for instance, the key file can gen-
erally be kept for 1–3 years in Sweden but can be kept for 
5 years in Finland (thereafter, a re-approval is needed), or 
must be destroyed immediately upon linkage (eg, for some 
studies in Iceland). The key file allows the government agency 
to re-match if the researchers detect errors in the dataset, but 
the key file also allows the researchers to request additional 
matching of data to their original dataset (after approval by 
the EC). An exception to the rule not to deliver identifiable 
data is the validation of diagnoses and procedures in the 
national health care registries. For validation purposes, the EC 
grants the researchers access to the PINs of a list of patients 
in order to request certain information (eg, patient charts for 
validation purposes).
Storage of data
Researchers must describe how collected data will be stored, 
who (which persons) will have access to the data, and for 
how long the data will be kept (with or without the PIN, 
and where potential coding lists are stored) (Table 2).19 In 
most registry-based projects, the applicant states that no 
procedures or extra data collection will be performed, that 
recording of data is carried out as part of routine health care 
(provided the researcher uses only data from the national 
health care registries), that the researchers will not have 
access to coding lists (if existing, the lists will be stored 
at the relevant government agency), and that data used for 
analyses are pseudonymized or anonymized. Biological 
samples obtained for research purposes must immediately 
be transferred to a biobank.
Biobanks
National laws in all Nordic countries, except Denmark, 
stipulate that the establishment of a new biobank must be reg-
istered at the National Board of Health and Welfare (Finland, 
688/2012; Iceland, 110/2000; Norway, LOV-2003-02-21-12 
for treatment and diagnostic biobanks and LOV-2008-06-
20-44 for research biobanks; and Sweden, 2002:297). Before 
a biobank is created in Finland, it must also be registered in 
the national biobank registry. Registration is done through 
a notice to the National Supervisory Authority for Welfare 
and Health (Valvira). The establishment of a new biobank 
must be authorized by the Minister of Health and Welfare 
and must be approved by the Directorate of Health, the Data 
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Ethical aspects in registry-based research
Protection Authority, and the central National Bioethics 
Committee (the EC) in Iceland.
The establishment of a biobank in Denmark requires 
approval either by the Danish Data Protection Agency if 
data are stored for future use only, or by the EC if the bio-
logical data are to be used in the specific project. According 
to the guidelines from the Danish Data Protection Agency, 
a biobank is considered a manual register. Where material 
from existing biobanks is used, the research projects are cat-
egorized as projects that include human biological material, 
and thus require approval from the EC. This includes both 
biobanks previously established for research purposes and 
clinical biobanks that are set up in connection with a person’s 
contact with the health service for clinical purposes, such as 
prevention, diagnostics, treatment, or care.
Earlier experience of the researcher
Furthermore, the EC requests researchers to describe their 
prior experience with registry-based research (for instance, 
Swedish ECs require that at least one of the participating 
researchers has a PhD degree). Relevant information entered 
into the EA may include a list of earlier EAs, earlier projects 
with a similar design, and experience of statistical elabora-
tion of national health care data. Some researchers will also 
describe their clinical experience of the disorders specified 
in the EA1.20
Risks and benefits of the research project
Registry-based research involves no invasive procedures, and 
the imposed risks on the study participants are few (Table 4) 
but do include the risk of breaching the participants’ integrity 
(when personal identity data are mismanaged and accessed by 
non-researchers, or presented at a very detailed level with very 
few persons in each stratum). Finally, political misuse of data 
may also occur. To minimize this risk, appropriate storage of 
data is necessary, and any key file should be stored away from 
the dataset used for statistical analyses. It is also necessary to 
state that extra care will be taken to reduce the potential risk 
of backward identification of individuals that could be based 
on combining detailed data. Meanwhile, it may seem like a 
paradox that while there is a strict framework surrounding 
medical registry-based research, many people seem willing to 
share their health data through the Internet or social media.
The benefits of using registry data are several: 1) there is no 
need to contact study participants; 2) large and unbiased study 
populations are available; and 3) data collection to the different 
registries is done independently, which minimizes bias in data 
collection. For instance, several research teams21–23 have shown T
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EA should include information on who informs the study par-
ticipants of the study. A written copy of the study information 
should be attached to the EA, including data on when and how 
informed consent is collected. This is particularly important 
when children or individuals with reduced cognitive abilities 
participate. In Denmark, researchers must provide arguments 
as to why studies using minors and other legally incompetent 
persons cannot recruit legally competent persons. Moreover, 
when processing an application for a study using minors, 
Danish ECs must consult an expert in pediatrics.
In registry-based research, researchers rarely request 
informed consent from individual study participants, because 
recent data suggest that such requirements lead to severe 
selection bias in large-scale observational research. The argu-
ments that informed consent is not needed for large-scale, 
registry-based studies in the Nordic countries include: 1) it 
would render many research proposals impossible because of 
the sheer number of study participants (sometimes more than 
1 million participants); 2) requesting individual approvals 
would dramatically reduce participation rates and statistical 
power of most nationwide population-based studies, which 
is a threat to the scientific validity of the study; 3) there is 
a risk that consent would be especially difficult to obtain in 
high-risk groups in which positive outcomes are most fre-
quent (selection bias28), such as in children and in immigrants 
with limited knowledge of the Nordic languages; 4) some 
individuals with registry-based information will be dead at 
the time the study is conducted, and thus, consent cannot be 
obtained; and 5) the costs of obtaining the consent of mil-
lions of individuals with health data would be exorbitant and 
would prohibit most large-scale research. These arguments 
conflict with the principles of justice and equality, which 
stipulate that individuals should not be discriminated against 
because of an inability to consent. Another feature of ECs in 
the Nordic countries is that they are generally acknowledged 
to represent the public, and that approval from the EC can 
largely replace individual approvals from study participants 
in registry-based research.
Publication of data
Finally, the EA requests information about how research data 
will be made public (generally through presentations at meet-
ings and through scientific manuscripts), and whether the data 
elaboration/statistical analyses are funded by, for instance, the 
pharmaceutical industry (and their influence on the research 
strategies). In addition, other economic relationships should 
be presented in the EA. Publication of data must guarantee 
the anonymity of individual patients, and data should be 
substantial selection bias when applying opt-in procedures in 
medical research; however, reasons for opting out may not 
constitute antipathy to research, but rather a misperception 
among the potential research subjects that their medical data 
are unlikely to benefit research,24 or an unawareness of the 
balance between scientific losses and confidentiality gains.25
Some research questions cannot be addressed in stud-
ies other than registry-based studies; for example, studies 
regarding safety of prenatal exposures, which are not ethical 
to perform as randomized trials, or studies with great public 
health interest for which it is difficult or unethical to recruit 
representative study populations, such as studies of suicide, 
mental illness, or drug use must be done as registry-based 
studies. Also, studies with long time follow-up, eg, cancer 
development or cardiovascular disease after drug exposure, 
require information reliably collected through registries.
Recruitment of study participants  
and informed consent
Recruitment of study participants, whether through contact 
between a physician and a patient, from contact during earlier 
studies, or from national registries (without contact with the 
patient) must be described in the EA. The researchers must 
argue their reasoning if they choose to exclude vulnerable 
individuals from the study. Researchers may also choose to 
underline that all population groups are actually included 
(to underscore that their study will also benefit a vulnerable 
population).26
An essential part of the EA concerns informed consent.27 
Although informed consent is crucial in intervention studies 
to preserve the confidence of the public, it is generally not 
required for large-scale, registry-based studies in the Nordic 
countries. Instead, it is assumed that the study participants 
do not object to registry-based research, provided that such 
research is deemed ethical by the EC. This assumed agreement 
to contribute personal data to research is part of the informal 
contract between the individual and the state (or where rel-
evant, county councils or other suppliers of health care), given 
that health care is traditionally virtually free of charge (costs 
are covered through the tax bill). Registry-based data are 
maintained for the purpose of health care quality improvement 
and national statistics and are used in economic administration 
systems, and transfer of data is sometimes an integrated part 
of the reimbursement system (single individuals cannot opt 
out; instead, participation is compulsory).
For studies in which the researcher contacts the study 
participants and informed consent is relevant (eg, in case of 
linkages with individual questionnaires or biological data), the 
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presented in aggregated form to eliminate the possibility of 
recognizing or identifying a specific person.29
Attachments to the EA
Table 5 lists documents that may be required at EA 
 submission. For clinical trial research, further documents 
may be relevant.
Safeguarding integrity and 
protecting vulnerable subjects
While it may seem evident that study participants have much 
to gain from registry-based research, they may experience 
considerable loss if integrity is breached. This gain/loss 
relationship also holds for the individual researcher, respon-
sible research institutions, and registry owners. Table 4 is an 
outline of the different actors in registry-based research, how 
potential problems can be overcome, and what each actor 
stands to gain from registry-based research.
Protection of personal data
The Swedish,30 Danish,31 and Icelandic Personal Data Acts 
classify personal data into sensitive and non-sensitive cat-
egories.32 All data on political and religious affiliations, as 
well as medical data, are classified as sensitive. All these data 
are “sensitive”, but some data (eg, data about sexual health) 
may be regarded as highly sensitive (we use the phrase highly 
sensitive here, though it is not defined in law).
Table 5 Attachments to the EA
Research plan (and when possible, information for laypersons) (DEN;# 
FiN;# iSL;# NOR;# SwE#)
Curriculum vitae for the responsible researcher (DEN;# FiN;# iSL;# 
NOR;# SwE#)
Certificate from the head of the department that a workplace is available 
for the researcher (DEN;§ FiN;§ iSL;§ NOR;§ SwE#)
List of participating researchers (DEN;# FiN;# iSL;# NOR;# SwE*)
Advertising material for recruitment of study participants (DEN;# FiN;# 
iSL;* NOR;# SwE*)
written study information when informed consent is relevant (DEN;# 
FiN;# iSL;# NOR;# SwE*)
Copy of the questionnaire or survey if used in the study (DEN;# FiN;# 
iSL;# NOR;# SwE*)
Description of economic compensation to study participants (DEN;# 
FiN;# iSL;* NOR;# SwE*)
Copy of contracts if the researcher is hired by a funder (DEN;* FiN;§ 
iSL;* NOR;* SwE*)
Notes: *Documents may be submitted as part of the EA; #documents must always 
be submitted as part of the EA; §not needed. in some Nordic countries, researchers 
must also submit their own evaluation of ethical dilemmas involved in the project, 
plus a description of the registry/registries used.
Abbreviations: DEN, Denmark; FiN, Finland; iSL, iceland; NOR, Norway; SwE, 
Sweden.
All archived data (ie, from surveys and blood samples) 
are held as strictly confidential. Relevant safety precautions, 
including firewalls, inhibit access from unknown users. Thus, 
only authorized researchers and database personnel have 
access to such data.
Despite safeguards, registry-based research still carries a 
small risk for breach of confidentiality (Table 4). However, 
in practice, such breaches have occurred only very rarely in 
the Nordic countries. A recent Nordic joint report described 
a research project involving individuals with mental illness in 
which patients had received an e-mail with e-mail addresses 
to all patients openly listed, and researchers breaching integ-
rity by including personal data on cancer on PowerPoint slides 
for a public meeting.33
Personal data officer
In Sweden, storage of personal research data must also be 
approved by a personal data officer (Swedish language, “Per-
sonuppgiftsombud”). The Swedish personal data officer is a 
function rather than an individual role. The idea is that the pub-
lic should know whom to contact in case they have questions. 
Some research bodies have a personal data officer that ensures 
that personal data are managed according to national laws. 
In this sense, the data officer is similar to an accountant, 
although the latter is responsible for financial transactions, 
whereas the former is responsible for personal data.
In Norway, a personal data officer (Norwegian language, 
“Personvernombud”) is a function that institutes and busi-
nesses may choose to engage. The personal data officer is 
administered by the Data Inspectorate and approves notifica-
tions of use and storage of personal data, while the Datains-
pektion must provide a license when this is needed.
In Finland, a registry notification (including a registry 
description of the person registered) needs to be made to the 
Data Protection Ombudsman only in registry-based research 
when processing automated, sensitive personal data directly 
from registries, not from the individual and without his/her 
consent. In research where all participants have given their 
informed consent on data collection, no registry notification 
needs to be made. Also, when applying for data from national 
health care registries, the registry authority consults the data 
protection ombudsman. In Finland, the Office of the data 
protection ombudsman is an independent authority operating 
in conjunction with the Ministry of Justice. The office is run 
by the data protection ombudsman, who is appointed by the 
Council of State for a term of 5 years.
The Data Protection Authority (local language, 
“Persónuvernd”) in Iceland is an independent authority 
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operating in conjunction with the Ministry of Internal 
Affairs, which implements acts on the protection of privacy 
and processes personal data, and conducts audits on the 
security of personal data. ECs in Iceland must report all 
received EAs to the Data Protection Authority and must 
obtain approval for the use and handling of personal data 
by researchers.
Denmark has no personal data officer system, but the Data 
Protection Authority there conducts audits on the security of 
storage and use of personal data.
vulnerability and children
Vulnerability refers to the inability of individuals to protect 
themselves from harm. Almost all registry-based research 
will involve vulnerable individuals. Traditionally, vulnerabil-
ity has not been considered in medical research,34,35 and exist-
ing EA guidelines from such establishments as the Swedish 
ECs only consider vulnerability indirectly, and therefore, 
urge researchers to consider the special circumstances related 
to children or individuals with limited decision skills. Other 
categories of vulnerable individuals include people with 
psychiatric disabilities and the homeless.
Knowledge about how vulnerable individuals experience 
research is scarce, but it seems that they generally have a 
positive experiences of research; however, a minority of these 
persons36 have experienced some form of distress. Among 
vulnerable patients participating in registry-based research 
are the very sick and sometimes unconscious patients. These 
patients, however, only participate indirectly in that their 
health care data are stored in the national registries outlined 
in Table S1 to the same extent as that of all other Nordic indi-
viduals seeking health care. Neither these nor other patients 
are usually contacted or asked to participate in registry-based 
research; instead, their interests are  represented by the EC.
Registry-based research generally includes children when 
1) they have seen a physician/been admitted to hospital, 
developed cancer, or given birth before the age of 18 years 
(or are selected as age-matched controls); 2) they are children 
to a father or mother in need of health care (if the research 
involves several generations); 3) they have a brother or sister 
who has been treated in the health care system (and sibling 
analyses are performed); or 4) they have received a dispensed 
drug (registered in a prescribed drug register).
Re-use of data already delivered  
to researchers
Re-use of existing data is usually cost-effective, decreases 
the need for additional data storage, and reduces the risk of 
data security breaches (when data are sent from government 
agencies to researchers). Re-use of data should preferably 
be consistent with the aim of the original study. The Nordic 
countries differ with regard to the stipulated need for new 
EAs before re-use of data. In Denmark and Finland, data 
can be re-used by the researcher without further addendum 
if the original approval from the data protection agency has 
not expired and if the new analyses are all within the field 
covered by this approval. Similar rules apply in Sweden 
and Iceland, although researchers from these countries 
are expected to submit an amendment to the EC, arguing 
why re-use of data is necessary. In Norway, a fully new 
EA is needed for the re-use of existing data for a different 
purpose.
Discussion
Over time, medical research has moved from descriptions of 
individual patients to applied statistics,37 and ever since the 
landmark studies of Doll and Hill,38,39 numerical follow-up 
has become more and more important in research; today, 
numerical follow-up is the hallmark of modern medicine.
The potential of Nordic registry research is formidable, as 
these countries have national health data sources and the pos-
sibility to combine data in a way not possible in other countries 
(Table 6). There is a growing interest in using and combin-
ing Nordic registries in research; however, today’s system 
for collecting and combining data within and between the Nor-
dic countries is discouraging and limits use of these resources. 
Common Nordic registry and epidemiology research meet 
many national obstacles when doing trans-Nordic research 
(NORIA-net on Registries).40 The problem of cross-border 
access in sharing sensitive individual medical information is 
the same whether it involves collaboration between national 
statistical agencies or between Nordic clinical researchers. 
The same holds for biobanks and tissue sampling, ie, existing 
national legislations in the Nordic countries make it difficult or 
impossible for a free exchange of sample and tissue informa-
tion between researchers in the Nordic countries. Further, for 
clinical interventional studies (eg, new treatments), different 
legislation and policies are not conducive to working on a 
common Nordic ground.
In addition to the cross-border issues in sharing registry 
data, today’s systems for obtaining approvals and eventually 
data in several of the Nordic countries are extremely slow 
and complicated, with numerous applications and approvals 
from data owners in addition to the mandatory ethical and 
data inspectorate approval. It often takes several years of EA 
submissions until data are available for statistical analysis. 
The time spent coordinating approvals and obtaining data for 
Nordic collaboration is therefore extensive for each project.
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In contrast, politicians, registry owners, institutions, and 
researchers are all promoting and welcoming increased use of 
registry-based data sources available in the Nordic countries. 
The public also shares expectations that information collected 
mandatorily through public registries and systems is used to 
improve knowledge on health and diseases, and for research 
purposes. Consequently, there is a need to create a common 
Nordic research area. The three main areas (registries, biobanks, 
and interventional research) have in common the idea that 
when human research is involved, approval by a research EC 
is  compulsory. So far, the discussion on a common Nordic 
research area has focused on the different legislations between 
the Nordic countries. We propose that common Nordic denomi-
nators for research ethical review must be created. A multina-
tional agreement between the Nordic countries on accepting 
ethical decisions from another Nordic country in research using 
human subjects, or mutual recognition, is suggested.
The reasons for the acceptance of ethical decisions made 
in other Nordic countries are the following: 1) the countries 
share a history that goes back more than 1,000 years; 2) there 
are large similarities between the countries’ ethical review 
systems; 3) the countries share religious, cultural, and ethical 
values; 4) the countries have in common a system for social 
welfare that guarantees respect for the individual; and 5) they 
share a common democratic allegiance.41 They also share a 
similar approach in how they analyze applications and IRBs 
are all staffed with laypersons, experts, and lawyers (Table 1). 
Thus, there are more similarities than differences between the 
countries regarding the content of the ethical review, even if 
the procedures vary from country to country.
Implementation of a multinational agreement would 
greatly reduce resistance to collaborative Nordic clinical 
research projects and thereby accelerate the process of 
developing new treatments to improve public health for 
Nordic citizens and welfare societies. Hence, the main driv-
ing force behind increased collaboration and use of Nordic 
data rather than merely national data should be the needs of 
the patients. Nordic collaboration in registry-based research 
has already yielded important results42–45 based on the vast 
array of national registries available in Denmark, Finland, 
Iceland, Norway, and Sweden (Table S1). For instance, 
merging data from all Nordic countries allows for studies of 
rare exposures or outcomes in the large study population of 
more than 25 million people combined. Other examples of 
unique Nordic research could be comparing and evaluating 
differences between the Nordic countries such as policies/
recommendations of medications use, incorporation of new 
medications, changes in vaccination programs, follow-up 
programs, etc.
Denmark, Finland, and Sweden are part of the European 
Union (EU), and will therefore be affected by the proposed 
EU general data protection regulation. This initiative is an 
effort by the European Commission to enforce a unified data 
protection framework for all member states in the EU.46 As 
members of the European Economic Area (EEA), Norway 
and Iceland will also most likely be affected by this new 
Table 6 Examples of Nordic registry-based studies
Etiology Article title
Lange et al50 Lung-function trajectories leading to chronic obstructive pulmonary disease
Larsson and wolk51 Dietary fiber intake is inversely associated with stroke incidence in healthy Swedish adults
Bolinder et al52 Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers
Naess et al53 Cardiovascular mortality in relation to birth weight of children and grandchildren in 500,000 Norwegian families
Prognosis
Granlund et al54 Diverticular disease and the risk of colon cancer – a population-based case-control study
Cantarutti et al55 Body mass index and mortality in men with prostate cancer
Holm et al56 Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality: results from a prospective cohort 
with a wide range of variation in alcohol intake
Kristinsson et al57 Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: a population-based study of 
1,555 patients diagnosed in Sweden from 1980 to 2005
Román et al58 Postmenopausal hormone therapy and the risk of breast cancer in Norway
Therapy
Lichtenstein et al59 Medication for attention deficit-hyperactivity disorder and criminality
Madsen et al60 Geographic analysis of the variation in the incidence of attention deficit–hyperactivity disorder (ADHD) in a 
country with free access to healthcare: a Danish cohort study
Pasternak and Hviid61 Use of proton-pump inhibitors in early pregnancy and the risk of birth defects
Lund et al62 Prescription drug use among pregnant women in opioid maintenance treatment
Stephansson et al44 Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality
Quality assessment
vestergaard et al63 Geographical variation in use of intensive care: a nationwide study
Kristiansen et al64 Off-hours admission and acute stroke care quality: a nationwide study of performance measures and case-fatality
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legislation. The current version of the regulation stipulates 
that research use of registry-based health care data does 
not require informed consent from all study participants. 
Should the next generation of the EU general data protec-
tion regulations require individual informed consents, truly 
population-based studies would no longer be possible in 
Denmark, Finland or Sweden.
Gillon identifies a number of ethical principles/areas that 
may be considered in registry-based research.47 Pros and cons 
of research are often summarized in a risk–benefit analysis. 
Our position is that the benefits of registry-based research 
to patients as well as to health care in general far outweigh 
potential liabilities. Safeguarding the integrity of the patient 
and that of the managing physician is crucial for acceptance 
by the Nordic health care registries. Misuse of registry-based 
data for political reasons is rare, but should that happen, data 
storage at independent universities (where data access is 
limited to academics) may be preferable to the current status 
where data are stored with government agencies. However, 
it should be noted that current regulations in the Nordic 
countries hinder misuse of data (by researchers, politicians, 
and others), regardless of where data is stored.
Individuals usually benefit from registry-based research 
in that the research increases knowledge about the natural 
history and risk factors associated with their disease. Given 
that registry-based research does not carry liabilities (physi-
cal or non-physical) to the study participants, we argue that 
research participants stand to gain more than they stand to 
lose from such research. Closely related to the discussion 
about the potential benefits of research is the contention that, 
for reasons of justice and equality, research should also be 
performed on all population sub-groups, in that exclusions 
due to such factors as age, sex, race, ethnicity, or country 
of birth, deprive these groups of relevant data about their 
diseases, prognoses, disease management, and follow-up 
treatment options.
In recent years, medical quality registries have become 
an important source of data in registry-based research.48 
Quality registries usually focus on a specific diagnosis (eg, 
prostate cancer49). As opposed to most national registries 
in the Nordic countries, participants in Swedish quality 
registries can choose not to participate. Research projects 
emanating from quality registries must undergo the same 
stringent assessment by the EC as other registry-based 
studies.
Conclusion
In conclusion, prevailing conditions for registry-based 
research are comparable in the Nordic countries, and 
researchers from these countries face similar issues. Although 
there are differences in the composition of ECs and the 
content of EAs, we feel that these differences can be bridged 
and dealt with positively with increasing collaboration and 
more high-quality research as ultimate goals.
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